Kezar Life Sciences to explore strategic alternatives

Kezar Life Sciences (KZR) announced regulatory updates and the initiation of a process to explore a full range of strategic alternatives focused on maximizing shareholder value. The will be implementing a restructuring plan including a workforce reduction and other cost-containment and cash conservation measures. The company intends to retain employees essential for supporting value creation as part of its strategic review. There can be no assurance that this process will result in the company pursuing a transaction or any other strategic outcome. The company has not set a timetable for completion of the process for evaluating strategic alternatives and does not intend to disclose further developments or guidance on the status of its programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary. As of September 30, 2025, the company’s cash, cash equivalents and marketable securities totaled approximately $90.2M. This preliminary estimate is not a comprehensive statement of the company’s financial results for the quarter ended September 30, 2025, and has not been audited, reviewed or compiled by its independent registered public accounting firm. The company’s actual consolidated cash, cash equivalents and marketable securities balance as of September 30, 2025, may differ from these estimates due to the completion of the company’s quarter-end closing procedures.